ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,521.52
-1.39%
Dow Jones
40,813.57
-1.30%
US Dollar vs MXN
20.08495
-0.01%
Brent Oil
69.795
-0.19%
Bitcoin
81,020.06
-0.02%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Plus Therapeutics Inc (PSTV)

  7. Plus Therapeutics Inc (PSTV) Noticias

PSTV

Plus Therapeutics (PSTV)

Plus Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PSTV
FechaHoraFuenteTítuloSímboloCompañía
10/03/202506:33Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PSTVPlus Therapeutics Inc
10/03/202506:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTVPlus Therapeutics Inc
10/03/202506:30GlobeNewswire Inc.Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity RequirementNASDAQ:PSTVPlus Therapeutics Inc
07/03/202506:30GlobeNewswire Inc.Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in GlioblastomaNASDAQ:PSTVPlus Therapeutics Inc
06/03/202506:30GlobeNewswire Inc.Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung CancerNASDAQ:PSTVPlus Therapeutics Inc
05/03/202515:01GlobeNewswire Inc.Plus Therapeutics Announces New Employment Inducement GrantsNASDAQ:PSTVPlus Therapeutics Inc
04/03/202513:06GlobeNewswire Inc.Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross ProceedsNASDAQ:PSTVPlus Therapeutics Inc
26/02/202506:30GlobeNewswire Inc.Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal MetastasesNASDAQ:PSTVPlus Therapeutics Inc
24/02/202506:30GlobeNewswire Inc.Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics SubsidiaryNASDAQ:PSTVPlus Therapeutics Inc
20/02/202516:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTVPlus Therapeutics Inc
20/02/202506:30GlobeNewswire Inc.Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development OfficerNASDAQ:PSTVPlus Therapeutics Inc
18/02/202506:30GlobeNewswire Inc.Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases ProgramNASDAQ:PSTVPlus Therapeutics Inc
10/02/202507:27Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PSTVPlus Therapeutics Inc
17/12/202406:30GlobeNewswire Inc.Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer SymposiumNASDAQ:PSTVPlus Therapeutics Inc
04/12/202406:30GlobeNewswire Inc.Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer SymposiumNASDAQ:PSTVPlus Therapeutics Inc
03/12/202406:30GlobeNewswire Inc.Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope SupplyNASDAQ:PSTVPlus Therapeutics Inc
25/11/202406:30GlobeNewswire Inc.Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual ConferenceNASDAQ:PSTVPlus Therapeutics Inc
22/11/202406:30GlobeNewswire Inc.Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal MetastasesNASDAQ:PSTVPlus Therapeutics Inc
21/11/202406:30GlobeNewswire Inc.Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal MetastasesNASDAQ:PSTVPlus Therapeutics Inc
14/11/202415:15GlobeNewswire Inc.Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:PSTVPlus Therapeutics Inc
06/11/202406:30GlobeNewswire Inc.Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing PartnershipNASDAQ:PSTVPlus Therapeutics Inc
05/11/202406:30GlobeNewswire Inc.Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024NASDAQ:PSTVPlus Therapeutics Inc
29/10/202406:30GlobeNewswire Inc.Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, TexasNASDAQ:PSTVPlus Therapeutics Inc
04/10/202415:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PSTVPlus Therapeutics Inc
01/10/202406:30GlobeNewswire Inc.Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual MeetingNASDAQ:PSTVPlus Therapeutics Inc
18/09/202406:30GlobeNewswire Inc.Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual MeetingNASDAQ:PSTVPlus Therapeutics Inc
04/09/202406:30GlobeNewswire Inc.Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:PSTVPlus Therapeutics Inc
23/08/202415:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PSTVPlus Therapeutics Inc
14/08/202415:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTVPlus Therapeutics Inc
14/08/202415:16GlobeNewswire Inc.Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:PSTVPlus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PSTV

Su Consulta Reciente

BOV
L1YB34R
LyondellBasell Industrie...
COIN
ELIXUSD
Elixir
COIN
BURSTUSD
Burst
COIN
WANUSD
WanCoin
COIN
AOLUSD
AOLCoin
NYSE
AEO
American Eagle Outfitters
BIT
F34657
Vontobel Financial Produ...
LSE
PU01
Sant Uk 26
LSE
XMJD
Xjapan
COIN
MTRAUST
MetaRare
COIN
SAV3USD
Sav3Token
TG
A19W01
Kingdom of Spain
LSE
97NP
Non C.m.1 A Frn
BIT
EMKT
Amundi MSCI Emerging Mar...
TSXV
JTC
Jemtec
LSE
TRIN
Trinity Exploration & Pr...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios